ChemoID test leads to better outcomes in platinum-resistant ovarian cancer
MSN highlights research published in npj Precision Oncology
MSN and MSN UK highlighted results from a new Phase 3 trial published in the journal npj Precision Oncology that found a cancer stem cell test can accurately choose more effective treatments and lead to improved outcomes for patients with platinum-resistant ovarian cancer.
The University of Cincinnati Cancer Center’s Thomas Herzog, MD, the study’s first author, said epithelial ovarian cancer often initially responds to chemotherapy treatment and then enters a period of resistance to therapy and tumor regrowth.
“This is partly due to the selection and reactivation of cancer stem cells (CSCs) that rebuild and repair the tumor from the damage received from chemotherapy,” said Herzog, a Cancer Center physician researcher, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center.
Pier Paolo Claudio, MD, who codeveloped the clinical test, said the ChemoID platform challenges the CSCs found in individual patients' tumors against specific anticancer drugs to identify which drugs are likely to be the most effective.
The 81 patients with platinum-resistant ovarian cancer (cancer recurrence within six months of receiving a platinum-based chemotherapy) enrolled in the trial were randomized to have the choice of chemotherapy treatment decided through ChemoID or to have physicians choose using standard methods. Herzog said doctors selecting treatments typically rely on approved therapies, past experiences, patients’ prior treatments, and toxicity or side effects patients have already experienced.
The overall response rate of patients in the ChemoID arm was 50%, compared to 5% for patients in the physician-choice arm. Median progression free survival for patients in the ChemoID arm was 11 months, compared to a median of three months for the physician-choice arm. ChemoID patients had a median duration of response of eight months, compared to five-and-a-half months for physician-choice.
Featured photo at top of ovarian cancer cells. Photo/OGPhoto/iStock.
Related Stories
Bazinga! UC physicist cracks ‘Big Bang Theory’ problem
December 19, 2025
A physicist at the University of Cincinnati and his colleagues figured out something two of America’s most famous fictional physicists couldn’t: theoretically how to produce subatomic particles called axions in fusion reactors.
A year of momentum at UC Law—and the path ahead
December 19, 2025
College of Law Dean Haider Hamoudi reflects on 2025 successes and shares a message about the future.
University of Cincinnati’s IDD Education Center to Host Ninth Annual Red & Black Blast
December 18, 2025
The University of Cincinnati’s IDD Education Center will host its ninth annual Red & Black Blast on February 25, 2026, at Tangeman University Center. The signature event celebrates and supports the Center’s four programs—CEES, TAP, IMPACT Innovation, and RAAC—which create pathways in education, employment, and community life for individuals with intellectual and developmental disabilities (IDD).